Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

ClinicalTrials.gov ID: NCT01058863

Public ClinicalTrials.gov record NCT01058863. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Randomized, Placebo-controlled, 5-way Crossover, Multicenter, Single-dose, Dose-ranging Study to Compare the Efficacy and Safety of Albuterol Spiromax® and ProAir® HFA in Adult and Adolescent Subjects Ages 12 and Older With Persistent Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is examining how well a dry powder inhaler (DPI) of albuterol medication works to help adult and adolescent subjects 12 years of age and older with persistent asthma to improve lung function.

Study identification

NCT ID
NCT01058863
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
72 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2010
Primary completion
May 31, 2010
Completion
May 31, 2010
Last update posted
Nov 8, 2021

2010

United States locations

U.S. sites
13
U.S. states
8
U.S. cities
13
Facility City State ZIP Site status
Teva Clinical Study Site Huntington Beach California 92647
Teva Clinical Study Site Rolling Hills Est. California 90274
Teva Clinical Study Site San Diego California 92123
Teva Clinical Study Site Colorado Springs Colorado 080907
Teva Clinical Study Site Margate Florida 33036
Teva Clinical Study Site Miami Florida 33173
Teva Clinical Study Site St Louis Missouri 63141
Teva Clinical Study Site Skillman New Jersey 08558
Teva Clinical Study Site Raleigh North Carolina 27607
Teva Clinical Study Site Cincinnati Ohio 45231
Teva Clinical Study Site Dayton Ohio 45406
Teva Clinical Study Site Medford Oregon 97504
Teva Clinical Study Site Portland Oregon 97213

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01058863, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01058863 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →